

Table S1. Clinical characteristics of dMMR CRC, pMMR CRC, and healthy controls.

	CTRL (n=227)	dMMR (n=21)	pMMR (n=207)	Pvalue (dMMR vs pMMR)
Age (Mean±SD)	50.41 ± 13.60	51.67 ± 12.53	55.25 ± 13.00	0.2256
Gender (%)				1
Female	128 (56.4)	9 (42.9)	88 (42.5)	
Male	99 (43.6)	12 (57.1)	119 (57.5)	
BMI (Mean±SD)	25.40 ± 3.48	22.78 ± 3.64	23.77 ± 3.24	0.2452
Location (%)				<0.0001
Right hemicolon	N/A	17 (81.0)	43 (20.8)	
Left hemicolon	N/A	4 (19.0)	67 (32.4)	
Rectum	N/A	0 (0.0)	97 (46.9)	
T Stage (%)				1
T3	N/A	17 (81.0)	169 (81.6)	
T4	N/A	4 (19.0)	38 (18.4)	
Size (%)				0.0237
<5cm	N/A	8 (38.1)	136 (65.7)	
≥5cm	N/A	13 (61.9)	71 (34.3)	
Differentiation (%)				0.0105
Well-Moderate	N/A	9 (42.9)	138 (66.7)	
Poor	N/A	11 (52.4)	69 (33.3)	
NA	N/A	1 (4.8)	0 (0.0)	
Nerve Invasion (%)				0.0484
Negative	N/A	14 (66.7)	121 (58.5)	
Positive	N/A	6 (28.6)	86 (41.5)	
NA	N/A	1 (4.8)	0 (0.0)	
Vascular Invasion (%)				0.0628
Negative	N/A	12 (57.1)	102 (49.3)	
Positive	N/A	8 (38.1)	105 (50.7)	
NA	N/A	1 (4.8)	0 (0.0)	
CEA (ng/ml) (Mean±SD)	N/A	10.43 ± 20.99	33.60 ± 122.03	0.0176
CA199 (U/ml) (Mean±SD)	N/A	113.97 ± 295.04	50.40 ± 146.09	0.3406
KRAS/NRAS/BRAF Mutation (%)				0.1567
Negative	N/A	7 (33.3)	108 (52.2)	
Positive	N/A	14 (66.7)	99 (47.8)	
Neoadjuvant Therapy (%)				0.1328
No	N/A	18 (85.7)	139 (67.1)	
Yes	N/A	3 (14.3)	68 (32.9)	

Abbreviations: CRC, colorectal cancer; dMMR CRC, deficient DNA mismatch repair CRC; pMMR CRC, proficient DNA mismatch repair CRC; CTRL, enrolled healthy controls; SD, standard deviation; N/A, not available. P values calculated by Student's t test or Pearson's Chi-square test. P < 0.05 is considered statistically significant.